Spanish presidency puts device issues on the EU table
This article was originally published in Clinica
Executive Summary
Although only seven weeks into its six-month tenure, the Spanish presidency of the EU Council is already looking like being one of the most proactive in terms of medical device regulation. Following on from some useful groundwork under the Belgian presidency, Spain's promise to include a resolution on devices at the final council meeting on June 26 comes at a time of when the profile of the devices industry is being raised in in many quarters in Europe.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.